Parexel International (ma) Corporation
Location
Massachusetts
Founded
1983-02-28
Website
Risk Signals
451 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Parexel International (ma) Corporation
Live alerts from global media, monitored by Business Radar
2024-10-19 (openpr.com)
Regulatory Affairs Outsourcing Market to Witness Stunning Growth | Major Giants Covance (USA), Parexel (USA), IQVIA (USA)
Press release - HTF Market Intelligence Consulting Pvt. Ltd. - Regulatory Affairs Outsourcing Market to Witness Stunning Growth | Major Giants Covance (USA), Parexel (USA), IQVIA (USA) - published on openPR.com
Read more
2024-09-18 (market.us)
Medical Writing Market Boom: Predicted $9.4 Billion Value by 2032
Medical Writing Market Size is expected to reach USD 9.4 Billion by 2032 from USD 3.6 Billion in 2022, growing at a CAGR of 10.4%.
Read more
2024-09-04 (businessfacilities.com)
Expansion And HQ Relocation Bring Jobs To North Carolina
Reliance Packaging LLC invests $2.7M to expand operations in Moore County, creating 32 jobs; Parexel relocates headquarters to a 61,076SF office in Raleigh, North Carolina.
Read more
2024-04-26 (expresspharma.in)
Parexel partners with Palantir to accelerate clinical data delivery
Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the safety and regulatory rigor
Read more
2024-01-16 (biovoicenews.com)
Parexel announces strategic alliance with Japanese Foundation for Cancer Research - BioVoiceNews
With experience spanning more than 115 years, JFCR is Japan’s first and largest medical organization dedicated to cancer care
Read more
2022-12-15 (globenewswire.com)
Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical Trials
New collaboration leverages MyEyeDr.’s 850+ offices across the US to refer patients into ophthalmology and other therapeutic area clinical trials, expands...
Read more
2022-12-15 (globenewswire.com)
Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical Trials
New collaboration leverages MyEyeDr.’s 850+ offices across the US to refer patients into ophthalmology and other therapeutic area clinical trials, expands...
Read more
2022-06-16 (globenewswire.com)
Parexel Expands Patient Access to Clinical Trials Through New Community Alliance Network
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across...
Read more
2022-06-14 (prnewswire.com)
Riverside Partners' Portfolio Company, Syner-G BioPharma Group, Appoints Ron Kraus as CEO
/PRNewswire/ -- Riverside Partners, a Boston based private equity firm, announced today that its portfolio company, Syner-G BioPharma Group ("Syner-G" or the...
Read more